Persbericht Biocartis Group NV: Biocartis kondigt succesvolle aandelenuitgifte met voorkeurrecht aan
November 29, 2022 09:15 ET
|
Biocartis NV
PERSBERICHT: VOORKENNIS / GEREGLEMENTEERDE INFORMATIE29 november 2022, 15:15 CET Biocartis kondigt succesvolle aandelenuitgifte met voorkeurrecht aan: Bestaande aandeelhouders en nieuwe investeerders...
Press release Biocartis Group NV: Biocartis Announces Successful Rights Offering
November 29, 2022 09:15 ET
|
Biocartis NV
PRESS RELEASE: INSIDE INFORMATION / REGULATED INFORMATION29 November 2022, 15:15 CET Biocartis Announces Successful Rights Offering: Existing Shareholders and New Investors Fully Subscribed for the...
Mainz Biomed Appoints Amy Levin as Vice President of Regulatory Affairs to Oversee Global Regulatory Strategies
November 29, 2022 08:00 ET
|
Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
POINT Biopharma Releases New Preclinical Data Supporting the Combination of 177Lu-PNT6555 with Immunotherapy
November 29, 2022 07:30 ET
|
POINT Biopharma
Combining 177Lu-PNT6555 with anti-PD-1 immunotherapy resulted in a significantly increased survival benefit compared to independent treatments in an anti-PD-1 resistant preclinical tumor model ...
Persbericht Biocartis Group NV: Kennisgeving aan de Obligatiehouders betreffende Verwachte Verplichte Conversie
November 28, 2022 11:45 ET
|
Biocartis NV
PERSBERICHT: GEREGLEMENTEERDE INFORMATIE 28 november 2022, 17:45 CET Kennisgeving aan de Obligatiehouders betreffende Verwachte Verplichte Conversie Bepalingen met een hoofdletter in deze...
Press release Biocartis Group NV: Expected Mandatory Conversion Bondholder Notification
November 28, 2022 11:45 ET
|
Biocartis NV
PRESS RELEASE: REGULATED INFORMATION 28 November 2022, 17:45 CET Expected Mandatory Conversion Bondholder Notification Capitalised terms not otherwise defined in this notice shall have the meaning...
Onconova Therapeutics to Present at the Upcoming RHK Capital Disruptive Growth Conference
November 28, 2022 08:00 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for...
Enlivex Receives Allocetra IND Clearance From The U.S. Food And Drug Administration For Treatment Of Patients with Advanced Solid Malignancies
November 28, 2022 08:00 ET
|
Enlivex Therapeutics Ltd
IND filing followed encouraging preclinical studies conducted in collaboration with Yale Cancer Center that showed a substantial, statistically significant survival benefit when Allocetra™ was...
Alpha Tau Medical Announces Third Quarter 2022 Financial Results and Provides Corporate Update
November 22, 2022 16:02 ET
|
Alpha Tau Medical Ltd.
JERUSALEM, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS and DRTSW), ("Alpha Tau" or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha...
Novartis highlights scientific advances with Kisqali, iptacopan, Scemblix and YTB323 data at SABCS and ASH
November 22, 2022 09:25 ET
|
Novartis Pharma AG
First data to be presented as a late-breaker abstract from global pivotal APPLY-PNH trial of investigational oral monotherapy iptacopan in paroxysmal nocturnal hemoglobinaria (PNH), a rare and...